Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

BACKGROUND. After erythropoiesis‐stimulating agent (ESA) failure, lenalidomide and hypomethylating agents are the only remaining treatment options for most patients with lower‐risk myelodysplastic syndromes (LR‐MDS). Optimal choice of these agents as front‐line therapy in non‐del(5q) LR‐MDS is uncle...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Komrokji, Rami, Swern, Arlene S., Grinblatt, David, Lyons, Roger M., Tobiasson, Magnus, Silverman, Lewis R., Sayar, Hamid, Vij, Ravi, Fliss, Albert, Tu, Nora, Sugrue, Mary M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2017
Aiheet:
Academia‐Pharma Intersect: Hematologic Malignancies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813747/
https://ncbi.nlm.nih.gov/pubmed/29118268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0215
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia